This website uses cookies so that we can provide you with the best user experience possible. Our Cookie Notice is part of our Privacy Policy and explains in detail how and why we use cookies. To take full advantage of our website, we recommend that you click on “Accept All”. You can change these settings at any time via the button "Update Cookie Preferences" in our Cookie Notice.
Technical cookies are required for the site to function properly, to be legally compliant and secure. Session cookies only last for the duration of your visit and are deleted from your device when you close your internet browser. Persistent cookies, however, remain and continue functioning on repeat visits.
Analytics cookies collect anonymised information such as the number of site visitors or most popular pages. These cookies “remember” that you have visited a website and this information may be shared with the providers of analytics services (see details in our privacy policy). Keeping these cookies enabled helps us improve our website and provide you with the most relevant content.
Personalisation cookies collect information about your website browsing habits and offer you a personalised user experience based on past visits, your location or browser settings. They also allow you to log in to personalised areas and to access third party tools that may be embedded in our website. Some functionality will not work if you don’t accept these cookies.
The shareholders of Haselmeier Group sold all shares in Haselmeier Group for an enterprise value of 100 million Euros to stock exchange listed Swiss company Sulzer AG.
Haselmeier Group, founded in 1920 and headquartered in St. Gallen with a development and production centre in Stuttgart, is a leading, own-IP provider of drug delivery devices such as subcutaneous self-injection pens for use in fast-growing indications such as reproductive health, growth disorders, osteoporosis and diabetes. Haselmeier employs approximately 230 people and achieved a turnover of around 36 million Euros in 2019.
By acquiring Haselmeier, Sulzer will complement its healthcare portfolio and strengthen its applicator systems division. Together with Sulzer's financial strength and know-how in precision injection moulding, the company will seize growth opportunities in the rapidly increasing drug delivery devices market. In addition, combining Sulzer's expertise in liquid mixing applications with Haselmeier's drug delivery competence will benefit Sulzer's pharmaceutical customers by providing them with innovative and sophisticated devices and services.
The transaction has been completed on 1 October 2020 in Zurich.
An international team from CMS, led by partners Stephan Werlen (CMS Zurich) and Stefan-Ulrich Müller (CMS Munich), advised the shareholders of Haselmeier Group on all legal matters of the transaction.
CMS Switzerland
CMS Germany
Social Media cookies collect information about you sharing information from our website via social media tools, or analytics to understand your browsing between social media tools or our Social Media campaigns and our own websites. We do this to optimise the mix of channels to provide you with our content. Details concerning the tools in use are in our privacy policy.